Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
13.94
+0.92 (7.07%)
At close: Aug 13, 2025, 4:00 PM
13.86
-0.08 (-0.57%)
Pre-market: Aug 14, 2025, 8:47 AM EDT
Zymeworks Revenue
Zymeworks had revenue of $48.73M in the quarter ending June 30, 2025, with 153.21% growth. This brings the company's revenue in the last twelve months to $122.87M, up 95.94% year-over-year. In the year 2024, Zymeworks had annual revenue of $76.30M with 0.38% growth.
Revenue (ttm)
$122.87M
Revenue Growth
+95.94%
P/S Ratio
8.55
Revenue / Employee
$429,605
Employees
286
Market Cap
1.05B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZYME News
- 3 days ago - Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - GlobeNewsWire
- 5 days ago - Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 17 days ago - Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - GlobeNewsWire
- 4 weeks ago - Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewsWire
- 2 months ago - Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) - Seeking Alpha
- 2 months ago - Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewsWire
- 2 months ago - Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewsWire